))
Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer
Manage episode 455215901 series 3525104
内容由Breastcancer.org提供。所有播客内容（包括剧集、图形和播客描述）均由 Breastcancer.org 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
At the 2024 San Antonio Breast Cancer Symposium, Dr. Aditya Bardia, director of the Breast Oncology Program and Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center, presented results from the DESTINY-Breast06 study, showing that Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki), also called T-DXd, was better than chemotherapy for metastatic, hormone receptor-positive, HER2-low or -ultralow breast cancer that grew after one or more hormonal therapy medicines.
Listen to the episode to hear Dr. Bardia explain:
- results of the study
- what HER2-low and -ultralow breast cancer is
- whether people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer should have additional HER2 testing
323集单集
分享
